Evidence map›Paper›PMID 35735457›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.

Anna V Tinker, Alon D Altman, Marcus Q Bernardini, Prafull Ghatage, Lilian T Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M Oza

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Anna V TinkerDivision of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Alon D AltmanDivision of Gynecologic Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada.ORCID 0000-0002-6345-4910
Marcus Q BernardiniDivision of Gynecologic Oncology, Princess Margaret Cancer Center, University Health Network, Sinai Health System, Toronto, ON M5B 2M9, Canada.
Prafull GhatageDepartment of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Lilian T GienDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1X8, Canada.
Diane ProvencherInstitut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 0A9, Canada.ORCID 0000-0003-1902-3256
Shannon SalvadorDepartment of Obstetrics and Gynecology, McGill University Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Sarah DoucetteIMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.
Amit M OzaDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1X8, Canada.
University Health Network · CACancerCare Manitoba · CACentre Hospitalier de l’Université de Montréal · CAFluidigm (Canada) · CAJewish General Hospital · CASunnybrook Health Science Centre · CAUniversity of British Columbia · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard of care maintenance therapy to prolong remission and prevent relapse following a response to first-line platinum-chemotherapy. Olaparib and niraparib are the PARP inhibitors currently approved for use in the first-line maintenance setting in Canada. Selection of maintenance therapy requires consideration of patient and tumour factors, presence of germline and somatic mutations, expected drug toxicity profile, and treatment access. This paper discusses the current clinical evidence for first-line PARP inhibitor maintenance therapy in patients with advanced, high-grade EOC and presents consensus statements and a treatment algorithm to aid Canadian oncologists on the selection and use of PARP inhibitors within the Canadian EOC treatment landscape.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsCanadaFemaleHumansMutationNeoplasm Recurrence, LocalPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsBRCAepithelial ovarian cancerhomologous recombination repairPARP inhibitors

Identifiers

PMID35735457
PMCPMC9221681
OpenAlexW4283020357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.